Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
16.96
+2.33 (15.93%)
At close: Nov 4, 2024, 4:00 PM
16.90
-0.06 (-0.35%)
After-hours: Nov 4, 2024, 5:53 PM EST

Company Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers.

It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.

Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer.

The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.

Monopar Therapeutics Inc.
Monopar Therapeutics logo
Country United States
Founded 2014
IPO Date Dec 19, 2019
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Chandler Robinson

Contact Details

Address:
1000 Skokie Boulevard, Suite 350
Wilmette, Illinois 60091
United States
Phone 847 388 0349
Website monopartx.com

Stock Details

Ticker Symbol MNPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $8.00
CIK Code 0001645469
CUSIP Number 61023L108
ISIN Number US61023L1089
Employer ID 32-0463781
SIC Code 2834

Key Executives

Name Position
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc Co-Founder, Chief Executive Officer, President and Director
Dr. Christopher M. Starr Ph.D. Co-Founder and Independent Executive Chairman of the Board
Andrew J. Cittadine M.B.A. Chief Operating Officer
Karthik Radhakrishnan CFA Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Dr. Patrice P. Rioux M.D., Ph.D. Acting Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 31, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 30, 2024 8-K Current Report
Oct 29, 2024 424B5 Filing
Oct 28, 2024 424B5 Filing
Oct 28, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 24, 2024 8-K Current Report
Oct 22, 2024 8-K Current Report
Oct 15, 2024 8-K Current Report
Oct 7, 2024 8-K Current Report